BASF is optimistic that its plant-biotechnology business will generate a considerable amount of money "in the middle of the current decade," a company official said. Stefan Marcinowski, a BASF board member, said the chemicals group's alliance with Monsanto on bioengineered maize and other crops could bring in more than $2 billion in gross sales by 2020.

Related Summaries